Zevra Therapeutics (ZVRA) & The Competition Critical Review

Zevra Therapeutics (NASDAQ:ZVRA) is one of 896 public companies in the “Pharmaceuticals” industry, but how does it weigh in compared to its competitors? We will compare Zevra Therapeutics to similar companies based on the strength of its profitability, dividends, earnings, analyst recommendations, valuation, institutional ownership and risk.

Risk and Volatility

Zevra Therapeutics has a beta of 1.01, indicating that its stock price is 1% more volatile than the S&P 500. Comparatively, Zevra Therapeutics’ competitors have a beta of -3.79, indicating that their average stock price is 479% less volatile than the S&P 500.

Analyst Recommendations

This is a breakdown of current ratings and target prices for Zevra Therapeutics and its competitors, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Zevra Therapeutics	0	1	9	1	3.00
Zevra Therapeutics Competitors	7769	13855	25724	1032	2.41

Zevra Therapeutics currently has a consensus target price of $27.14, suggesting a potential upside of 164.55%. As a group, “Pharmaceuticals” companies have a potential upside of 25.40%. Given Zevra Therapeutics’ stronger consensus rating and higher probable upside, equities research analysts clearly believe Zevra Therapeutics is more favorable than its competitors.

Valuation and Earnings

This table compares Zevra Therapeutics and its competitors gross revenue, earnings per share and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
Zevra Therapeutics	$106.47 million	$83.23 million	11.15
Zevra Therapeutics Competitors	$3.55 billion	$3.17 billion	547.98

Zevra Therapeutics’ competitors have higher revenue and earnings than Zevra Therapeutics. Zevra Therapeutics is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.

Profitability

This table compares Zevra Therapeutics and its competitors’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Zevra Therapeutics	42.82%	54.54%	34.15%
Zevra Therapeutics Competitors	-2,372.59%	-220.83%	-15.99%

Institutional and Insider Ownership

35.0% of Zevra Therapeutics shares are owned by institutional investors. Comparatively, 32.6% of shares of all “Pharmaceuticals” companies are owned by institutional investors. 3.7% of Zevra Therapeutics shares are owned by company insiders. Comparatively, 14.1% of shares of all “Pharmaceuticals” companies are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.

Summary

Zevra Therapeutics beats its competitors on 9 of the 13 factors compared.

About Zevra Therapeutics

Zevra Therapeutics, Inc. discovers and develops various proprietary prodrugs to treat serious medical conditions in the United States. The company develops its products through Ligand Activated Therapy platform. Its lead product candidate is KP1077, consisting of KP1077IH, which is under Phase 2 clinical trial for the treatment of idiopathic hypersomnia, and KP1077N, which is under Phase ½ clinical trial to treat narcolepsy. The company is also developing Celiprolol, a prodrug product candidate that is under Phase 1/2 clinical trial for the treatment of vascular Ehlers Danlos syndrome. In addition, it offers AZSTARYS, a once-daily treatment for attention deficit hyperactivity disorder in patients aged six years and older; OLPRUVA to treat urea cycle disorders; and Arimoclomol for the treatment of niemann pick disease type C, an ultra-rare neurodegenerative lysosomal storage disorder. The company has collaboration and license agreement with Commave Therapeutics SA to develop, manufacture and commercialize the company’s product candidates containing SDX and d-methylphenidate; and license agreement with Acer and Relief Therapeutics, Inc. to develop and commercialize rights for OLPRUVA. The company was formerly known as KemPharm, Inc. and changed its name to Zevra Therapeutics, Inc. in February 2023. Zevra Therapeutics, Inc. was incorporated in 2006 and is headquartered in Celebration, Florida.